These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 19075528)

  • 1. [Current state and the future of molecular target drugs: lessons learned from the success of imatinib].
    Yamada H
    Nihon Yakurigaku Zasshi; 2008 Dec; 132(6):339-42. PubMed ID: 19075528
    [No Abstract]   [Full Text] [Related]  

  • 2. Cross-resistance of imatinib mesylate and 17-AAG in imatinib-resistant cells that overexpress BCR-ABL.
    Topaly J; Schad M; Laufs S; Melo JV; Zeller WJ; Fruehauf S
    Br J Haematol; 2003 May; 121(4):672-3. PubMed ID: 12752112
    [No Abstract]   [Full Text] [Related]  

  • 3. Gleevec resistance: lessons for target-directed drug development.
    Daley GQ
    Cell Cycle; 2003; 2(3):190-1. PubMed ID: 12734421
    [No Abstract]   [Full Text] [Related]  

  • 4. Discontinuing imatinib in chronic myeloid leukemia: don't try this at home.
    Mattison R; Larson RA
    Leuk Lymphoma; 2009 Jun; 50(6):868-70. PubMed ID: 19455466
    [No Abstract]   [Full Text] [Related]  

  • 5. Rare frameshift mutation Cys475Tyrfs(*)11 in the BCR/ABL kinase domain contributes to imatinib mesylate resistance in 2 Korean patients with chronic myelogenous leukemia.
    Park SH; Chi HS; Kwon MR; Cho YU; Jang S; Park CJ
    Ann Lab Med; 2012 Nov; 32(6):452-4. PubMed ID: 23130349
    [No Abstract]   [Full Text] [Related]  

  • 6. Imatinib mesylate noncompliance simulating chronic myeloid leukemia resistance.
    Sandoval C; Giamelli J; Jayabose S
    J Pediatr Hematol Oncol; 2003 Jun; 25(6):507-8. PubMed ID: 12794534
    [No Abstract]   [Full Text] [Related]  

  • 7. Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to Imatinib.
    Irving JA; O'Brien S; Lennard AL; Minto L; Lin F; Hall AG
    Clin Chem; 2004 Jul; 50(7):1233-7. PubMed ID: 15229152
    [No Abstract]   [Full Text] [Related]  

  • 8. Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.
    Markose P; Chendamarai E; Balasubramanian P; Velayudhan SR; Srivastava VM; Mathews V; George B; Viswabandya A; Srivastava A; Chandy M
    Leuk Lymphoma; 2009 Dec; 50(12):2092-5. PubMed ID: 19925053
    [No Abstract]   [Full Text] [Related]  

  • 9. Chronic myeloid leukemia. Sceptical scientists.
    Druker BJ
    Lancet; 2001 Dec; 358 Suppl():S11. PubMed ID: 11784560
    [No Abstract]   [Full Text] [Related]  

  • 10. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance.
    Kantarjian HM; Talpaz M; Giles F; O'Brien S; Cortes J
    Ann Intern Med; 2006 Dec; 145(12):913-23. PubMed ID: 17179059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia.
    Bazeos A; Marin D; Reid AG; Gerrard G; Milojkovic D; May PC; de Lavallade H; Garland P; Rezvani K; Apperley JF; Goldman JM; Foroni L; Khorashad JS
    Leukemia; 2010 Jun; 24(6):1243-5. PubMed ID: 20445576
    [No Abstract]   [Full Text] [Related]  

  • 12. BCR/ABL amplification in chronic myelocytic leukemia blast crisis following imatinib mesylate administration.
    Campbell LJ; Patsouris C; Rayeroux KC; Somana K; Januszewicz EH; Szer J
    Cancer Genet Cytogenet; 2002 Nov; 139(1):30-3. PubMed ID: 12547154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is telomerase a player in chronic phase chronic myeloid leukemia, disease progression and imatinib resistance?
    White DL
    Leuk Lymphoma; 2008 Jun; 49(6):1022-3. PubMed ID: 18452091
    [No Abstract]   [Full Text] [Related]  

  • 14. A case with coexistence of major and minor BCR/ABL fusion transcript at lymphoblastic crisis of chronic myelogenous leukemia in patients with major BCR/ABL positivity during chronic phase.
    Park SH; Chi HS; Cho YU; Jang S; Park CJ; Im HJ
    Ann Lab Med; 2013 Jan; 33(1):80-3. PubMed ID: 23301228
    [No Abstract]   [Full Text] [Related]  

  • 15. Imatinib mesylate.
    Am J Health Syst Pharm; 2001 Dec; 58(23):2241-2. PubMed ID: 11765724
    [No Abstract]   [Full Text] [Related]  

  • 16. Targeting oncogene dependence and resistance.
    Hingorani SR; Tuveson DA
    Cancer Cell; 2003 May; 3(5):414-7. PubMed ID: 12781357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of BCR-ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype.
    Grant H; Jiang X; Stebbing J; Foroni L; Craddock C; Griffiths M; Clark RE; O'Brien S; Khorashad JS; Gerrard G; Wang L; Irving JA; Wang M; Karran L; Dyer MJ; Forrest D; Page K; Eaves CJ; Woolfson A
    Leukemia; 2010 Oct; 24(10):1817-21. PubMed ID: 20739956
    [No Abstract]   [Full Text] [Related]  

  • 18. ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.
    Ferreira AF; Moura LG; Tojal I; Ambrósio L; Pinto-Simões B; Hamerschlak N; Calin GA; Ivan C; Covas DT; Kashima S; Castro FA
    Blood Cells Mol Dis; 2014; 53(1-2):47-55. PubMed ID: 24629639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecularly targeted treatment of chronic myeloid leukemia: beyond the imatinib era.
    Mughal TI; Goldman JM
    Front Biosci; 2006 Jan; 11():209-20. PubMed ID: 16146726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transgenomic's WAVE System used for the early detection of drug resistance mutations in chronic myeloid leukemia.
    Pharmacogenomics; 2005 Jul; 6(5):458-9. PubMed ID: 16013994
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.